QIMR changes its name
08 August, 2013In recognition of a large gift from a donor, QIMR will now be known as the QIMR Berghofer Medical Research Institute.
Patrys myeloma trial to move to final group
07 August, 2013 by Dylan Bushell-EmblingPatrys (ASX:PAB) has received safety board approval to move to the final group in its multidose escalation study of PAT-SM6 in multiple myeloma.
TGA miscounted clinical trial numbers
05 August, 2013 by Dylan Bushell-EmblingThe Therapeutic Goods Administration has upwardly revised its statistics on Australian clinical trial notifications from 2009-2012, after discovering errors in its earlier reports.
GTG raising up to $10.6m for BREVAGen expansion
01 August, 2013 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) is conducting a capital raising worth up to $10.6m and will use the funds to expand its US market reach for breast cancer risk test BREVAGen.
New WHO centre in Sydney
31 July, 2013A new WHO centre for chronic diseases has been established in Sydney.
Chronic inflammatory disease on trial
31 July, 2013 by Susan WilliamsonThe results of clinical trial using cellular therapy in patients with Crohn’s disease were so encouraging the research was published before the trail had been completed.
Healthcare Management and Leadership unit launched at MGSM
30 July, 2013 by Lauren DavisMacquarie Graduate School of Management (MGSM) has launched a new unit for MBA students, ‘Healthcare Management and Leadership’, which will be offered for the first time in term four 2013 to those that wish to lead, govern or manage within the healthcare sector.
Gtech International to merge with Simavita Holdings
30 July, 2013Gtech International Resources, subsidiary of Genetic Technologies, has moved to acquire Simavita Holdings.
Bionomics begins safety program for cancer antibody
29 July, 2013 by Dylan Bushell-EmblingBionomics (ASX:BNO) has launched IND-enabling pharmacology and toxicology studies for BNC101, its anticancer antibody candidate.
Invion opens phase II trial for chronic bronchitis
26 July, 2013Recruitment has begun for Invion’s phase II trial that aims to repurpose nadolol as a treatment for smoking cessation.
Patrys doses third group in multiple myeloma trial
24 July, 2013Patrys (ASX:PAB) has completed initial treatment for the third of four groups of patients in a phase I/IIa trial of the company’s anticancer antibody, PAT-SM6, in multiple myeloma.
BioDiem progresses liver disease vaccine
24 July, 2013BioDiem (ASX: BDM) has announced its hepatitis vaccine program is making good progress.
New neuroscience facility opens in Sydney
23 July, 2013The new $54 million Neuroscience Research Australia facility has been officially opened in Sydney.
Invion commences phase II clinical trial in lupus
19 July, 2013Invion (ASX:IVX) has commenced patient enrolment in the company’s phase II clinical trial of INV103 in patients with mild systemic lupus erythematosus (lupus).
Viralytics reports strong interim results for cancer treatment
19 July, 2013Interim results look promising for Viralytic’s lead compound Cavatak.
